The rapid AVLAYAH revenue ramp and strong Q4 guidance validate commercial execution and support the platform thesis. Watch for Q4 actuals and the zafinofusp alfa BLA submission in 2027, which would be the second product approval.
Drug in focus
DNLI drug pipeline →tividenofusp alfa-eknm
● Neutral Named in this 8-K- Impact
- Phase
- Approved (accelerated approval)
- Time to market
- Already approved and commercially launched in the U.S. (March 2026). Global regulatory submissions are expected to follow the ongoing Phase 2/3 COMPASS confirmatory trial.
- Next catalyst
- None dated
What to watchThe next near-term catalyst is Denali's Q3 2026 earnings report on November 4, 2026, where management's Q3 Avlayah revenue (guided $10-12M, up from $3.6M in Q2) will be the key commercial proof point. The longer-term binary is the confirmatory Phase 2/3 COMPASS trial readout, which will determine whether the accelerated approval converts to full approval, though no specific readout date has been announced.
Price Chart
Executive Summary
Denali reported Q3 2026 AVLAYAH net product revenue of $17.8M, accelerating from $3.6M in Q2, and guided Q4 2026 revenue to $30M-$32M. Net income of $70.1M included a one-time $194M gain on a Priority Review Voucher sale. The company ended the quarter with $1.0B in cash and reiterated a 2027 BLA submission for zafinofusp alfa seeking accelerated approval.
Key Financial Metrics
Key Facts
- AVLAYAH net product revenue accelerated to $17.8M in Q3 2026, its second full commercial quarter
- Q4 2026 net product revenue guidance of $30.0M to $32.0M
- Net income of $70.1M included a one-time $194.0M net gain on sale of a Priority Review Voucher
- Cash, cash equivalents and marketable securities were approximately $1.0B as of September 30, 2026
- BLA submission for zafinofusp alfa (Sanfilippo syndrome type A) on track for 2027 seeking accelerated approval
- Five TransportVehicle programs expected to generate data in 2027
- Payer coverage now exceeds 70% of U.S. commercial lives, up from more than 50% in the prior quarter
- A permanent J-code became effective October 1, 2026, streamlining billing and reimbursement
Financial Impact
AVLAYAH revenue grew from $3.6M in Q2 to $17.8M in Q3, with Q4 guidance of $30M-$32M indicating continued acceleration. The company holds $1.0B in cash.
Risk Factors
- AVLAYAH revenue growth may not sustain at the guided Q4 rate due to patient population size or payer dynamics
- Zafinofusp alfa BLA submission and accelerated approval remain subject to FDA review and data adequacy
- Net income was driven by a one-time PRV gain; operating losses continue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001714899-26-000107 |
| Document: dnli-20261103.htm | 0001714899-26-000107 |
| Document: 0001714899-26-000107-index-headers.html | 0001714899-26-000107 |
| Document: 0001714899-26-000107-index.html | 0001714899-26-000107 |
| Document: 0001714899-26-000107.txt | 0001714899-26-000107 |
| 8-K Data (Synthetic) | 0001714899-26-000107 |
Track record
17 reports on DNLI
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +23.19% at T+60 after the May 7, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.75 Now $18.08 −3.55% settles Nov 17
- Nov 3, 202613d ago 8-K Bullish 6/10 Viewing No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $20.96 to $19.72 Now $18.08 −13.74% ▼ −5.92% −1.51% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $18.94 to $18.86 Now $18.08 −4.54% ▼ −0.42% +0.06% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $18.66 Now $18.08 −3.11% No price data
- Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $21.40 to $21.09 Now $18.08 −15.51% ▼ −1.45% −2.30% vs SPY
- Sep 4, 202610w ago Insider Cluster Neutral 2/10 Entry $22.08 to $21.57 Now $18.08 −18.12% ▼ −2.31% −1.84% vs SPY
- Aug 6, 202614w ago 8-K Mixed 6/10 Entry $24.83 to $25.00 Now $18.08 −27.18% ▲ +0.68% +0.71% vs SPY
- Jul 27, 202616w ago Press Release Neutral 1/10 Entry $24.05 Now $18.08 −24.82% No price data
- Jun 18, 202621w ago 8-K Bullish 6/10 Entry $23.31 to $24.05 Now $18.08 −22.44% ▲ +3.17% +3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers